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given during the study, and no clear method of how the outcome was evaluated was presented with the results. [12] [13] [14] The Skinner vaccine, an inactivated subunit vaccine containing mixed HSV-2 glycoproteins, reduced severity of recurrences in men and lowered the number of recurrences in women. 15 However, the vaccine showed no consistent pattern of efficacy or immunogenicity. 12 The TA-HSV-2 vaccine, a disabled infectious single cycle (DISC) virus vaccine, uses an HSV-2 strain with glycoprotein H deleted and completes only a single cycle of replication, never producing infectious progeny. However, development of this vaccine was stopped when phase II trials showed no protection against recurrences. 7, 10, 12 The most promising recent therapeutic vaccine trials have focused on development of recombinant glycoprotein vaccines and live-attenuated virus vaccines. The best recombinant glycoprotein vaccine results were seen in the gD2-alum vaccine trial which administered glycoprotein D2 with adjuvant alum. Vaccine recipients had 36% fewer culture-proven recurrences than the control group, and over the one year period of the trial had a median of two fewer total recurrences. 12, 16 In an attempt to improve upon this vaccine, gD2 was combined with gB2 and administered with the stronger adjuvant MF59. When evaluated, the gD2gB2-MF59 vaccine did not significantly reduce the monthly rate of recurrences or the duration of virus shedding; however it did significantly reduce symptom duration, new lesion formation and lesion duration. 12, 17 Nevertheless, the manufacturer stopped the trial due to the lack of reduction in recurrence rate. Promising live-attenuated virus vaccine results were seen in the ICP10DPK phase I/II clinical trials, which administered a deletion mutant virus lacking the PK domain of an essential viral protein. The vaccine completely prevented recurrences in 37.5% and 43.5% of the vaccinated patients in the first 18 and second 10 trials, respectively. The first trial also showed that the vaccinated patients who did have recurrences experienced them at a lower frequency compared with the placebo group. 10, 18 This vaccine has yet to undergo safety and efficacy trials, and thus, has not yet been approved for therapeutic use.
Ideally, a therapeutic HSV-2 vaccine will completely prevent viral shedding recurrences as well as transmission to a sex partner.
However, current research has produced vaccines that only partially fulfill these objectives. 8, 19 Therefore we developed a new mathematical model of the HSV-2 epidemic that accounts for the potentially imperfect therapeutic effects of the vaccines. We use the model to determine the potential public health impact therapeutic HSV-2 vaccines could have on reducing HSV-2 incidence if given to HSV-2 infected individuals. We evaluate two measures: (1) vaccine effectiveness (the cumulative percent reduction in new infections) and (2) vaccine efficiency (the cumulative number of new infections prevented per 100 individuals vaccinated). We evaluate effectiveness and efficiency for the general population in the US, where HSV-2 prevalence is currently 22%. 1 In addition, we identify which vaccine characteristic would have the greatest impact on increasing (or decreasing) vaccine effectiveness and efficiency.
mEthodS
Therapeutic HSV-2 vaccine model. We develop a new mathematical model of the HSV-2 epidemic which predicts and quantifies the effect of administering therapeutic vaccines to infected individuals; a flow diagram of our model is shown in Figure 1 . As in our previous models, [20] [21] [22] our new model contains the intrinsic dynamics of HSV-2 infection; thus infected individuals oscillate between a viral shedding stage (which includes both symptomatic and asymptomatic individuals) and a quiescent or latent stage. We assume that individuals can only transmit HSV-2 when they are shedding virus, but this transmission can occur from symptomatic and asymptomatic individuals. Within our modeling framework susceptible individuals enter the sexually active population at rate p and become infected with HSV-2 according to the contact rate c and the time-dependent per capita force of infection l, which is the product of the HSV-2 transmission probability (b for unvaccinated and b v for vaccinated individuals) and the probability of selecting an infectious partner; therefore l(t)=b(H(t)/N(t))+b v (H v 
(t)/N(t)),
where N(t) represents the population size of the sexually active community at a given time t, and H(t) and H v (t) respectively represent the infectious unvaccinated and vaccinated population size at a given time t. The average period of acquisition of new sex partners is 1/m. A certain proportion p of the infected individuals are vaccinated; the proportion e of vaccinated individuals in which the vaccine has a therapeutic effect (i.e. the vaccine "takes") is considered "successfully vaccinated." However, we assume that vaccine-induced therapeutic effects in the successfully vaccinated will eventually wane at rate w. Unvaccinated and vaccinated individuals will reactivate viral shedding at rates r and r v , respectively, which are calculated from the average length of a viral shedding episode (1/q and 1/q v for unvaccinated and vaccinated individuals, respectively), and the average number of viral shedding episodes per year (N E and N Ev for unvaccinated and vaccinated individuals, respectively); specifically 1/r = 1/N E -1/q and 1/r v = 1/N Ev -1/q v for unvaccinated and vaccinated individuals, respectively. The rate of reactivation increases with the average length of viral shedding episodes and the average number of episodes per year. We assume the therapeutic vaccine has three effects in successfully vaccinated individuals: the average length of their viral shedding episodes decreases (1/q v < 1/q), they have fewer viral shedding episodes per year (N Ev < N E ), and they have a lower probability of transmitting infection (b v < b) in comparison with unvaccinated infected individuals. Model equations are given in the Appendix.
Uncertainty and sensitivity analyses. Using time-dependent uncertainty analyses, we predict the impact of imperfect therapeutic HSV-2 vaccines given to HSV-2 infected individuals over a 30-year period. To account for uncertainty in parameter values, we use a range of values, and then sample the parameter ranges using Latin hypercube sampling (LHS). 20, 21, 23, 24 Table 1 shows parameter ranges used for the uncertainty analysis. Simulations were run 1,000 times (each simulation using a unique parameter set). Effectiveness (cumulative percent reduction in new infections) and efficiency (cumulative number of new infections prevented per individual vaccinated) were calculated each year for each simulation. To identify key parameters in increasing (or decreasing) effectiveness and efficiency, time-dependent sensitivity analyses were carried out by calculating partial rank correlation coefficients (PRCCs), as previously described. 20, 24 PRCCs were calculated to determine the relative sensitivity of the outcome variables (effectiveness and efficiency) to variation in the input parameters. Parameters with positive PRCC values have the effect of increasing the outcome value as they increase; parameters with negative PRCC values have the effect of decreasing the outcome variable as they decrease.
We conducted these uncertainty and sensitivity analyses for a moderate HSV-2 epidemic in which seroprevalence is 22%. We also performed the analyses for higher risk populations, in which HSV-2 seroprevalence is 60%.
Parameter estimates. Parameter ranges are given in Table 1 . HSV-2 infection parameters (b, N E , 1/q) are given ranges consistent with current data on HSV-2 pathogenesis. [25] [26] [27] [28] [29] We assume that the average duration of therapeutic HSV-2 vaccines (1/w) could range from 10-20 years; this assumption is based upon the durations of current prophylactic vaccines for smallpox, polio and diphtheria. 30, 31 We vary therapeutic vaccine parameters fairly broadly in order to investigate the impact of a wide range of hypothetical therapeutic vaccines. Therefore, we vary the proportion of infected individuals that are vaccinated (p) from 0.3-0.9, and the proportion of vaccinated individuals in whom the vaccine takes (e) from 0.3-1.0. We investigate the impact of therapeutic vaccines that (1) reduce the probability of transmission by 30-100%, (2) reduce the number of viral shedding episodes per year by 30-90% and (3) reduce the average viral shedding episode length by 30-90%. The average length of time acquiring new sex partners (1/m) was varied from 10-20 years. 23 The rate that new susceptibles enter the sexually active population (p) was varied from 10,000-20,000 individuals per year. By using LHS we are able to vary the values of all parameters at once, and thus investigate the potential public health impact of 1,000 different therapeutic vaccines.
rESultS

Predicted effectiveness and efficiency of therapeutic vaccines.
Assuming parameter ranges given in Table 1 , therapeutic HSV-2 vaccines could substantially reduce new HSV-2 infections over 30 years. Our predictions show the effectiveness (cumulative percent reduction in new infections) of a therapeutic vaccine would rise quickly over the first five years of vaccination, and then slowly level off over the next 25 years ( Fig. 2A) . After five years, 43% (median; IQR, 34-52%) of cumulative new infections would be prevented, and after 30 years, 77% (median; IQR, 70-83%) of cumulative new infections would be prevented ( Fig. 2A) .
Our predictions also show that the efficiency (cumulative new infections prevented per individual vaccinated) of a therapeutic vaccine would rise steadily over time (Fig. 2B) . After five years of vaccinating infected individuals, the vaccine would prevent 0.17 a Uniform probability distribution functions (pdfs) were used for all parameters except N E which used a triangular pdf with a peak value of 12 per year and 1/q which used a triangular pdf with a peak value of 3.5 days. Figure 3A and B respectively. The effectiveness of the vaccine is most sensitive to variation in the take (e) and the proportion of infected individuals vaccinated (p) (Fig. 3A) .
In contrast, efficiency is most sensitive to the average length of time an individual spends acquiring new sex partners (1/m) (Fig. 3B) ; as the average sexual life span increases, efficiency decreases. The sensitivity of the vaccine effectiveness and efficiency to the average duration of vaccine-induced therapeutic effects in successfully vaccinated individuals (1/w) changed dramatically over time, having relatively no sensitivity to this parameter when vaccination begins, and having relatively high sensitivity to this parameter after 15 years of vaccination. After about ten years of vaccination, efficiency becomes more sensitive to 1/w than to the proportion vaccinated (p) or the proportion in which the vaccine takes (e). This phenomenon does not occur for vaccine effectiveness. Other important though relatively less influential parameters for both effectiveness and efficiency were the vaccine-induced reduction in the transmission probability (b v /b), the vaccine-induced reduction in episode length (q/q v ), and the vaccine-induced reduction in number of episodes per year (N Ev /N E ). Variations in the ranges of the remaining parameters were found to have relatively little effect 
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Imperfect Therapeutic HSV-2 Vaccines in increasing (on decreasing) effectiveness and efficiency. Results were similar for high HSV-2 prevalence (60%) epidemics. The sensitivity of effectiveness and efficiency to key vaccine characteristics, shortly after the introduction of therapeutic vaccines, is shown in Figure 4 . Figure 4A shows the effect of vaccine coverage (p) and vaccine take (e) on effectiveness after five years of vaccination. Reductions in cumulative new infections of 15-30%, 30-45%, 45-60% or 60-75% are shown (Fig. 4A) . The greatest reduction in cumulative new infections after five years occurs when both coverage levels and vaccine take are maximized; for example, a therapeutic vaccine with a vaccine take of 85% administered to 85% of sexually-active HSV-2 infected individuals would have an effectiveness of 60-75%. However, a therapeutic vaccine with a vaccine take of 40% administered to only 40% of sexually-active HSV-2 infected individuals would only have an effectiveness of 15-30%. Figure 4B shows the effect of vaccine duration (1/w) and the vaccine-induced reduction in transmission probability (b v /b) on efficiency after 30 years. Prevention of 0.65-0.80, 0.80-0.95, and 0.95-1.10 cumulative infections per indvidual vaccinated are shown (Fig. 4B) . These results quantify the projected effect of vaccine duration and vaccine-induced reduction in transmission probability on efficiency (Fig. 4B) . For example, a therapeutic vaccine that reduces the probability of transmission by 90% in Figure 4C . These results show that vaccine efficiency is greatest the more the vaccine reduces the length of viral shedding episodes or the number of episodes per year, i.e., when the relative length (g) or number (z) of viral shedding episodes are minimal.
diScuSSioN
Our results have shown that imperfect therapeutic vaccines could be extremely effective, reducing cumulative new infections by 77%, and preventing 0.84 cumulative new infections for each vaccinated individual after 30 years of vaccination. Effectiveness (cumulative percent reduction in new infections) will increase rapidly in the first years after the vaccine is introduced, and begin to level off after 15 years of vaccination. Efficiency (cumulative number of new infections prevented per individual vaccinated) will be fairly low initially, but over time, will steadily increase, making vaccination programs become more "efficient" with time. Our results have important implications for therapeutic HSV-2 vaccine development and vaccination strategies. We have shown that vaccine "take" and coverage are key characteristics for maximum effectiveness and efficiency, especially in the short term, and so it follows that high initial vaccination coverage levels are essential, as are adjuvants that induce a high vaccine take. After the first five years of vaccination, vaccine duration will be an important factor determining vaccine 
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efficiency; booster vaccinations that increase duration may be needed to sustain high efficiency over time. The strong and consistent negative correlation of efficiency with the length of time individuals acquire new sex partners indicates the importance of behavioral intervention strategies that shorten the period of acquiring new partners. Finally, our results show that the epidemic-level measures of effectiveness and efficiency were more sensitive to reduction in transmission probability than to therapeutic benefits that accrue directly to the infected individual, specifically, reduction in the number and length of viral shedding 26 episodes. Thus, to control the HSV-2 epidemic, current vaccine development efforts should target mechanisms that reduce asymptomatic and symptomatic viral shedding (thereby reducing transmission) in an effort to provide maximum individual-level therapeutic benefit and epidemic-level infection-prevention benefit. Such vaccines, which interfere with virus production, would consequently reduce the number of viral particles shed by cells per unit time. There is a precedent for this kind of therapeutic intervention; for example antiviral therapy reduces viral shedding.
There are some potential limitations of our model that warrant discussion. Our model excludes aspects of HSV-2 epidemiology such as differences due to gender and age. In this study we do not include stratification by subgroups; instead our goal is to model novel therapeutic HSV-2 vaccines in order to predict the reduction in new infections for the entire population. Therefore our conclusions apply to the combined population, but they do not address subpopulations by age or gender. Differences in gender may not be substantial in the context of therapeutic vaccines. The gender difference found in phase III trials for a prophylactic vaccine involved protection against clinical disease and not infection: a subset of HSV-seronegative women showed a reduction in disease and a non-statistically significant trend toward reduction in infection. 6 The current study is concerned with reduction in infection. Our study addressed differences in risk behavior and ethnicity by considering high risk populations in which HSV-2 incidence is 60%. We found equivalent results for such populations as for the general US population (where HSV-2 prevalence is 22%). Therefore the same vaccines, used in both moderate and high risk populations (such as in developing countries, men who have sex with men and those of African descent), will be expected to have approximately the same impact, independent of HSV-2 prevalence.
The potential public health impact of imperfect vaccines has been previously evaluated for HIV-1 vaccines, TB vaccines, and pre-exposure HSV-2 vaccines. 30, [32] [33] [34] [35] [36] [37] These studies have shown that even imperfect vaccines could have substantial public health impact, even with moderate vaccine efficacy and coverage levels; 30, [32] [33] [34] [35] [36] [37] it is even possible that imperfect vaccines could eradicate HIV-1 epidemics. 34, 35 Our current results on therapeutic HSV-2 vaccines are in accord with these previous results for imperfect vaccines for other diseases.
Our results can be used to generate predictions of the potential impact that imperfect therapeutic vaccines could have on controlling the HSV-2 epidemic. Considering the current rate of new infections in the United States, 38 imperfect therapeutic HSV-2 vaccines could prevent 212,600 (median; IQR, 156,064-288,558) new infections after only one year. This reduction translates to 24 (median; IQR, 18-33) infections prevented per hour every day, after the first year of vaccination alone. HSV-2 is also a risk factor for both infection and transmission of HIV-1; 39-45 the impact of HSV-2 epidemics increasing the incidence of HIV has recently been quantified and shown to be high. 46 Thus, HIV-1 infections can also be prevented if HIV-infected individuals are able to use future therapeutic HSV-2 vaccines.
We have recently evaluated the potential public health impact of imperfect prophylactic HSV-2 vaccines. 36 We found that their effectiveness and efficiency are likely to be modest, as compared to imperfect therapeutic HSV-2 vaccines. Previously, 36 we determined that moderately effective prophylactic HSV-2 vaccines are likely to reduce incidence only by 20%, (as compared to our predictions of incidence reductions of 77% for therapeutic vaccines) and that prophylactic HSV-2 vaccines would prevent only 0.11 infections per individual vaccinated (as compared to our current predictions of preventing 0.84 infections per individual vaccinated). Thus, we suggest that therapeutic vaccines would be substantially more useful than prophylactic vaccines for controlling HSV-2 epidemics because a high proportion of the general population is already infected with HSV-2; 22% of the general population in the US is HSV-2 infected. Thus, this epidemic is not restricted to behavior core-groups, and therapeutic vaccines that target large numbers of infected individuals who transmit HSV-2 are essential to controlling the epidemic. Obviously, it is also necessary to develop prophylactic vaccines and target them to younger individuals who are initiating sexual activity; however, even if these vaccines protect these individuals from infection, they should not be expected to have a major effect on reducing the incidence of HSV-2. Targeting virological core groups for daily antiviral therapy could also prove to be an extremely novel and effective control strategy for reducing HSV-2 epidemics. 23 However, therapeutic vaccines that lower the risk of HSV-2 transmission would be an improvement upon antiviral therapy, considering single administration of a vaccine, potentially followed by booster vaccinations. 26 Thus prevention efforts may benefit from therapeutic HSV-2 vaccines given to virological core groups of individuals who reactivate and shed infectious virus frequently; this potential should be explored. Though it is likely that a combination of prophylactic and therapeutic vaccines and antivirals will be necessary to fully control HSV-2 epidemics, therapeutic HSV-2 vaccines alone will provide a great degree of both epidemic and individual level benefit. The size of the sexually active population is N = X + H + H v + Q + Q v . The rate at which new susceptibles enter the sexually active population is p = mN. Pre-vaccine equilibrium values for X(t), H(t), and Q(t), denoted by X * , H * , and Q * , respectively, are given by
The initial HSV-2 prevalence
The contact rate, c, is derived from the pre-vaccine equilibrium conditions and initial HSV-2 population prevalence (22% or 60%) and is therefore
